TrialBritish journal of cancer2007

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.

N Starling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.